Trial Profile
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary) ; Pilocarpine (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Allergan
- 25 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Jul 2014 New trial record